MCID: INT068
MIFTS: 60

Intestinal Disease

Categories: Fetal diseases, Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Intestinal Disease

Summaries for Intestinal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to inflammatory bowel disease and colitis, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Iron and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include small intestine, testes and colon, and related phenotypes are Increased cell migration and homeostasis/metabolism

Wikipedia : 76 The gastrointestinal tract (digestive tract, digestional tract, GI tract, GIT, gut, or alimentary canal)... more...

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 32.0 TRPV1 TNF TLR9 NOD2 DEFB4A AREG
2 colitis 30.2 UCN TNF TLR9 TFF3 NOD2 MLH1
3 ulcerative colitis 30.1 UCN TNF NOD2 MLH1 CTNNB1
4 gastritis 29.8 AREG DEFB4A GHRL
5 irritable bowel syndrome 29.8 TLR9 TNF TRPV1
6 adenocarcinoma 29.7 TP53 MLH1 KRAS HRAS CTNNB1
7 colorectal adenocarcinoma 29.7 TP53 MLH1 KRAS HRAS CTNNB1 CEACAM5
8 colorectal cancer 29.4 TP53 TNF TLR9 TFF3 MLH1 KRAS
9 alpha-heavy chain disease 11.7
10 crohn's disease 11.3
11 protozoal dysentery 11.3
12 alpha chain disease 11.3
13 cystoisosporiasis 11.1
14 sitosterolemia 10.7
15 bile acid synthesis defect, congenital, 1 10.7
16 diarrhea 5, with tufting enteropathy, congenital 10.7
17 inguinal hernia 10.7
18 umbilical hernia 10.7
19 short bowel syndrome 10.7
20 blind loop syndrome 10.7
21 cecal disease 10.7
22 diverticulitis 10.7
23 epilepsy occipital calcifications 10.7
24 heavy chain disease 10.4
25 granulomatous endometritis 10.4 SDC1 CEACAM5
26 cryptosporidiosis 10.4
27 nasal cavity adenocarcinoma 10.4 TP53 KRAS HRAS
28 liver angiosarcoma 10.4 TP53 KRAS HRAS
29 tongue disease 10.4 TP53 TLR9 CTNNB1
30 biliary tract neoplasm 10.4 TP53 KRAS HRAS
31 ampulla of vater cancer 10.4 TP53 KRAS HRAS
32 prostate squamous cell carcinoma 10.4 TP53 HRAS CEACAM5
33 type 1 diabetes mellitus 15 10.4 GCG HRAS
34 sigmoid neoplasm 10.4 KRAS HRAS CEACAM5
35 mature b-cell neoplasm 10.4 TP53 TLR9 SDC1 BCL6
36 mixed cell type cancer 10.4 TP53 HRAS CEACAM5
37 apocrine adenoma 10.4 KRAS HRAS CEACAM5
38 gastroesophageal reflux 10.4 TRPV1 TP53 GHRL GCG
39 lung benign neoplasm 10.4 TP53 KRAS HRAS
40 aggressive digital papillary adenocarcinoma 10.4 KRAS HRAS CEACAM5
41 atrophic gastritis 10.4 GHRL TNF TP53
42 male reproductive system disease 10.4 TRPV1 TP53 TLR9 AREG
43 cecum adenocarcinoma 10.4 MLH1 KRAS HRAS
44 lichen planus 10.4 TP53 TNF TLR9 DEFB4A
45 bacterial pneumonia 10.4 TRPV1 TLR9 DEFB4A
46 mucinous lung adenocarcinoma 10.4 KRAS HRAS AREG
47 hypersensitivity reaction type iv disease 10.4 TNF TLR9 NOD2
48 middle ear disease 10.4 TNF TLR9 AREG
49 esophageal disease 10.4 TRPV1 TP53 CEACAM5
50 tonsillitis 10.4 DEFB4A TLR9 TNF

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Ischemic Heart Disease Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation, diarrhea, signs and symptoms, digestive, anal or rectal pain

GenomeRNAi Phenotypes related to Intestinal Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell migration GR00055-A-3 8.92 CTNNB1 HRAS KRAS SDC1

MGI Mouse Phenotypes related to Intestinal Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 AREG BCL6 CTNNB1 F5 GHRL HPS4
2 cellular MP:0005384 10.25 BCL6 CTNNB1 HPS4 KRAS MLH1 NOD2
3 digestive/alimentary MP:0005381 10.24 AREG CTNNB1 GHRL HRAS KRAS MLH1
4 cardiovascular system MP:0005385 10.22 AREG BCL6 CTNNB1 F5 HPS4 HRAS
5 hematopoietic system MP:0005397 10.2 AREG BCL6 CTNNB1 HPS4 KRAS MLH1
6 endocrine/exocrine gland MP:0005379 10.18 AREG BCL6 CTNNB1 GHRL HRAS KRAS
7 immune system MP:0005387 10.18 AREG BCL6 CTNNB1 KRAS MLH1 NOD2
8 integument MP:0010771 10.11 AREG CTNNB1 F5 HPS4 HRAS KRAS
9 liver/biliary system MP:0005370 9.87 BCL6 CTNNB1 F5 KRAS TNF TP53
10 neoplasm MP:0002006 9.86 CTNNB1 HRAS KRAS MLH1 SDC1 TNF
11 no phenotypic analysis MP:0003012 9.7 BCL6 CTNNB1 HRAS KRAS TNF TP53
12 renal/urinary system MP:0005367 9.5 CTNNB1 HPS4 HRAS KRAS TLR9 TP53
13 vision/eye MP:0005391 9.23 AREG CTNNB1 HPS4 KRAS MLH1 SDC1

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
2
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
3
Copper Approved, Investigational Phase 4,Not Applicable 7440-50-8 27099
4
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6
5
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
6
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
10
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
11
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
12
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81103-11-9 84029
13
Rifabutin Approved, Investigational Phase 4,Phase 3 72559-06-9 6323490
14
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2 2030-63-9 2794
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
16
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2 95058-81-4 60750
17
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
18
Etoposide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
21
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
22
Ifosfamide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
23
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
24
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
25
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
26
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
28
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
29
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 42399-41-7 39186
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
31 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
33
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 103577-45-3, 138530-94-6 9578005
34
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 103577-45-3 3883
35
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
36
Ceftriaxone Approved Phase 4,Not Applicable 73384-59-5 5479530 5361919
37
Trimebutine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 39133-31-8
38
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
39
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 17902-23-7 5386
40
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
41
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
42
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
43
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
44
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 114-07-8 12560
45
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
46
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Early Phase 1 6493-05-6 4740
47
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-21-8 3385
48
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
49
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
50
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3

Interventional clinical trials:

(show top 50) (show all 9326)
# Name Status NCT ID Phase Drugs
1 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
2 Single-Operator Versus Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
3 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
4 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
5 Vitamin D Substitution During Winter Time Unknown status NCT02958501 Phase 4 Colecalciferol
6 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
7 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
8 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
9 Double- Versus Single-balloon Enteroscopy for Obscure Small-bowel Bleeding Unknown status NCT01176864 Phase 4
10 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
11 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
12 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
13 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
14 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
15 Does Clinical Response Correlate With Serum Certolizumab Levels? Unknown status NCT02597829 Phase 4 Certolizumab Pegol
16 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
17 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
18 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
19 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
20 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
21 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
22 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
23 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
24 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
25 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
26 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
27 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
28 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
29 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
30 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
31 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
32 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
33 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
34 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
35 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
36 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
37 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
38 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
39 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
40 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
41 Oral vs Intravenous and Proton Pump Inhibitor (PPI)for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
42 Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer Unknown status NCT00471029 Phase 4 esomeprazole
43 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
44 The Use of DPP-4 Inhibitors in Short Bowel Syndrome Unknown status NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
45 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
46 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
47 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
48 A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula Unknown status NCT02423330 Phase 4
49 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
50 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

MalaCards organs/tissues related to Intestinal Disease:

41
Small Intestine, Testes, Colon, Liver, Bone, B Cells, Tongue

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

19
The Intestine

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 566)
# Title Authors Year
1
Toxic Causes of Intestinal Disease in Horses. ( 29397222 )
2018
2
Socioeconomic status and infectious intestinal disease in the community: a longitudinal study (IID2 study). ( 29016791 )
2018
3
Altered gut microbiota associated with intestinal disease in grass carp (Ctenopharyngodon idellus). ( 29777414 )
2018
4
Identifying free-text features to improve automated classification of structured histopathology reports for feline small intestinal disease. ( 29188759 )
2018
5
Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease. ( 29778465 )
2018
6
Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )
2018
7
Surgical Management of Abomasal and Small Intestinal Disease. ( 29249602 )
2018
8
Avian Influenza Virus Subtype H9N2 Affects Intestinal Microbiota, Barrier Structure Injury, and Inflammatory Intestinal Disease in the Chicken Ileum. ( 29783653 )
2018
9
Necroptosis in inflammatory bowel disease and other intestinal diseases. ( 30510938 )
2018
10
A Data-Based Hypothesis That Inflammatory Bowel Disease Unclassified (IBD-U) May Indicate That IBD Is a Spectrum of a Single Infectious Intestinal Disease. ( 30295733 )
2018
11
Interactions of helminths with macrophages: therapeutic potential for inflammatory intestinal disease. ( 30113218 )
2018
12
Metastatic vulvovaginal Crohn disease in the setting of well-controlled intestinal disease. ( 30235375 )
2018
13
Gastric wall fat halo sign in patients without intestinal disease. ( 30521990 )
2018
14
Comparison of 2 differently sized endoscopic biopsy forceps in the evaluation of intestinal disease in cats. ( 30556184 )
2018
15
Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. ( 29303974 )
2018
16
Stool PCR for Gastrointestinal Pathogens in Patients With and Without Immune-Mediated Intestinal Diseases. ( 29411208 )
2018
17
Three-year colonoscopy surveillance after polypectomy in Korea: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter prospective study. ( 29422807 )
2018
18
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. ( 29593540 )
2018
19
The Interleukin-20 Cytokines in Intestinal Diseases. ( 29967613 )
2018
20
Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. ( 30016852 )
2018
21
Pathomimetic modeling of human intestinal diseases and underlying host-gut microbiome interactions in a gut-on-a-chip. ( 30037458 )
2018
22
Complications of percutaneous endoscopic and radiologic gastrostomy tube insertion: a KASID (Korean Association for the Study of Intestinal Diseases) study. ( 30132209 )
2018
23
Mesenchymal stromal cell therapy in intestinal diseases. ( 30300331 )
2018
24
Socioeconomic status is associated with symptom severity and sickness absence in people with infectious intestinal disease in the UK. ( 28645256 )
2017
25
Recurrent diarrhoea in a renal transplant recipient: Early immunoproliferative small intestinal disease may be missed if not considered. ( 28205353 )
2017
26
Mechanisms and function of autophagy in intestinal disease. ( 29130415 )
2017
27
An Ontology to Improve Transparency in Case Definition and Increase Case Finding of Infectious Intestinal Disease: Database Study in English General Practice. ( 28958989 )
2017
28
Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. ( 28589631 )
2017
29
Whole-Blood Taurine Concentrations in Cats With Intestinal Disease. ( 28626960 )
2017
30
Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease. ( 28622393 )
2017
31
Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. ( 28194152 )
2017
32
Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study. ( 27356264 )
2017
33
Do surveillance intervals in patients with more than five adenomas at index colonoscopy be shorter than those in patients with three to four adenomas? A Korean Association for the Study of Intestinal Disease study. ( 27862272 )
2017
34
AMP-activated protein kinase: a therapeutic target in intestinal diseases. ( 28835570 )
2017
35
Helminths as an alternative therapy for intestinal diseases. ( 28970717 )
2017
36
Clinicopathological features of laterally spreading colorectal tumors and their association with advanced histology and invasiveness: An experience from Honam province of South Korea: A Honam Association for the Study of Intestinal Diseases (HASID). ( 28977010 )
2017
37
Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. ( 29126267 )
2017
38
Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. ( 29183720 )
2017
39
Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. ( 27338135 )
2017
40
Risk of advanced colorectal neoplasm in patients with more than 10 adenomas on index colonoscopy: A Korean Association for the Study of Intestinal Diseases (KASID) study. ( 27785837 )
2017
41
Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening? ( 28000563 )
2017
42
Heavy rainfall and risk of infectious intestinal diseases in the most populous city in Vietnam. ( 28012659 )
2017
43
We are not alone: a case for the human microbiome in extra intestinal diseases. ( 28286571 )
2017
44
The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. ( 28498331 )
2017
45
Roles of amino acids in preventing and treating intestinal diseases: recent studies with pig models. ( 28616751 )
2017
46
Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. ( 28670230 )
2017
47
Sopping up IL-22 drives intestinal disease. ( 27846535 )
2016
48
Thromboembolism in Dogs with Protein-Losing Enteropathy with Non-Neoplastic Chronic Small Intestinal Disease. ( 27841681 )
2016
49
A new anastomosis technique for intestinal diseases with proximal dilated segments. ( 27046984 )
2016
50
18F-FDG PET imaging for identifying the dynamics of intestinal disease caused by SFTSV infection in a mouse model. ( 26700962 )
2016

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1 Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1 Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 AREG CTNNB1 HRAS KRAS TNF TP53
2 12.77 CTNNB1 HRAS KRAS MLH1 TP53
3 12.7 AREG HRAS KRAS TNF TP53
4
Show member pathways
12.7 CTNNB1 HRAS KRAS MLH1 TP53
5
Show member pathways
12.7 AREG CTNNB1 HRAS KRAS MLH1 TP53
6
Show member pathways
12.65 CTNNB1 HRAS KRAS SDC1 TP53
7
Show member pathways
12.47 CTNNB1 HRAS KRAS TNF TP53
8
Show member pathways
12.41 AREG CTNNB1 HRAS KRAS TP53
9
Show member pathways
12.38 CTNNB1 HRAS KRAS TP53
10
Show member pathways
12.33 CTNNB1 HRAS KRAS SDC1
11
Show member pathways
12.32 HRAS KRAS SDC1 TNF TP53
12
Show member pathways
12.25 HRAS SDC1 TNF TP53
13
Show member pathways
12.16 CTNNB1 GCG GHRL UCN
14
Show member pathways
12.14 CEACAM5 HRAS KRAS SDC1
15
Show member pathways
12.11 HRAS KRAS TLR9 TNF
16 12.06 CTNNB1 HRAS KRAS TNF TP53
17 11.95 CTNNB1 SDC1 TNF TP53
18 11.91 HRAS KRAS TNF TP53
19 11.81 HRAS KRAS TNF TP53
20 11.77 CTNNB1 HRAS KRAS TP53
21 11.74 CTNNB1 HRAS KRAS SDC1 TNF TP53
22 11.68 HRAS KRAS TP53
23 11.67 CTNNB1 HRAS KRAS TP53
24 11.62 HRAS KRAS TP53
25 11.61 HRAS KRAS TP53
26 11.61 BCL6 CTNNB1 HRAS KRAS TP53
27 11.55 CTNNB1 HRAS TNF
28 11.51 HRAS KRAS MLH1 TP53
29 11.43 SDC1 TLR9 TNF
30 11.42 HRAS KRAS TNF
31 11.37 HRAS TNF TP53
32 11.32 CTNNB1 KRAS MLH1 TLR9 TNF TP53
33 11.26 HRAS KRAS TP53
34 11.02 CTNNB1 HRAS KRAS
35 10.78 HRAS KRAS

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 AREG DEFB4A F5 GCG GHRL TFF3
2 extracellular region GO:0005576 9.32 CEACAM5 DEFB4A F5 GCG GHRL SDC1
3 basolateral plasma membrane GO:0016323 9.26 CEACAM5 CTNNB1 NOD2 TLR9

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.96 BCL6 CTNNB1 NOD2 TP53
2 cell proliferation GO:0008283 9.96 AREG CTNNB1 GCG HRAS TP53
3 negative regulation of gene expression GO:0010629 9.95 CTNNB1 HRAS TNF UCN
4 defense response to bacterium GO:0042742 9.95 DEFB4A NOD2 TLR9 TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 GCG HRAS NOD2 TNF
6 positive regulation of apoptotic process GO:0043065 9.92 BCL6 CTNNB1 TNF TP53 TRPV1
7 positive regulation of protein phosphorylation GO:0001934 9.89 HRAS KRAS TNF UCN
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 CTNNB1 NOD2 TLR9 TNF
9 cytokine-mediated signaling pathway GO:0019221 9.88 BCL6 KRAS SDC1 TNF TP53
10 inflammatory response GO:0006954 9.88 BCL6 SDC1 TLR9 TNF TRPV1 UCN
11 regulation of cell proliferation GO:0042127 9.87 BCL6 CTNNB1 GHRL TNF
12 negative regulation of apoptotic process GO:0043066 9.87 BCL6 CEACAM5 CTNNB1 GCG GHRL TP53
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 GCG TNF UCN
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 KRAS NOD2 TLR9 TNF
15 regulation of inflammatory response GO:0050727 9.8 BCL6 NOD2 TNF
16 Ras protein signal transduction GO:0007265 9.79 HRAS KRAS TP53
17 negative regulation of cell differentiation GO:0045596 9.79 BCL6 CTNNB1 KRAS
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.75 NOD2 TLR9 TNF
19 positive regulation of JNK cascade GO:0046330 9.73 HRAS NOD2 TLR9 TNF
20 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.63 TLR9 TNF
21 positive regulation of interleukin-8 production GO:0032757 9.63 NOD2 TLR9 TNF
22 response to isolation stress GO:0035900 9.6 HRAS KRAS
23 positive regulation of MAP kinase activity GO:0043406 9.56 HRAS KRAS NOD2 TNF
24 positive regulation of corticotropin secretion GO:0051461 9.55 GHRL UCN
25 positive regulation of cortisol secretion GO:0051464 9.54 GHRL UCN
26 maintenance of gastrointestinal epithelium GO:0030277 9.54 NOD2 TFF3 TLR9
27 positive regulation of gene expression GO:0010628 9.5 CTNNB1 HRAS KRAS TLR9 TNF TP53
28 gastric emptying GO:0035483 9.49 GHRL UCN
29 positive regulation of interleukin-6 production GO:0032755 9.46 NOD2 TLR9 TNF UCN
30 response to glucocorticoid GO:0051384 9.02 AREG KRAS SDC1 TNF UCN
31 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 CTNNB1 HRAS NOD2 TLR9 TNF TP53
32 regulation of signaling receptor activity GO:0010469 10.02 AREG GCG GHRL TNF UCN

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AREG BCL6 CTNNB1 DEFB4A F5 GCG
2 identical protein binding GO:0042802 9.17 BCL6 CEACAM5 GCG SDC1 TNF TP53

Sources for Intestinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....